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ABSTRACT
Introduction. Cross-sectional GWAS on creatinine-estimated GFR (eGFRcrea) 
identified 53 SNPs. These SNP effects can be aggregated into a Genetic Risk 
Score (GRS) for chronic kidney disease (CKD). To assess its clinical utility, we 
examined associations with creatinine-estimated kidney outcomes, both cross-
sectionally and longitudinally. Additionally, we examined associations with 
cystatin C-estimated kidney outcomes to verify that a GRS based on eGFRcrea 
SNPs represents the genetics underlying kidney function. 
Methods. In the community-based PREVEND Study, we assessed eGFRcrea and 
eGFRcysc at baseline and four follow-up examinations. The GRS comprised 53 
SNPs for eGFRcrea weighted for reported effect-sizes. We adjusted for baseline 
demographics and renal risk factors.
Results. We included 3649 subjects (median age 49 years, 52% male, median 
follow-up 11 years, N=85 baseline CKD, N=154 incident CKD). At baseline, a 
higher GRS associated with lower eGFRcrea (adjusted B (95%CI) = -2.05 (-2.45;-
1.65) mL/min/1.73m2, p<0.001) and higher CKD prevalence (adjusted OR (95%CI)= 
1.41 (1.12;1.77), p=0.002). During follow-up, a higher GRS associated with higher 
CKD incidence (adjusted HR (95%CI)= 1.28 (1.09;1.50), p=0.004), but no longer 
significantly after adjustment for baseline eGFR. No significant association with 
eGFRcrea decline was found. Associations with cystatin C-estimated outcomes 
were similar. 
Conclusions. The GRS robustly associated with baseline CKD and eGFR, 
independent of known risk factors. Associations with incident CKD were likely due 
to low baseline eGFR, not accelerated eGFR decline. The GRS for eGFRcrea likely 
represents the genetics underlying kidney function, not creatinine metabolism or 
underlying etiologies. To improve clinical utility of GWAS results for CKD, these 
need to specifically address eGFR decline and CKD incidence. 
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INTRODUCTION
Chronic kidney disease (CKD) is a heterogeneous group of diseases defined by the 
presence of sustained reduced kidney function or kidney damage. Strong evidence 
exists for a genetic component to CKD risk: CKD has been observed to aggregate 
in families1-3 and heritability estimates are reported to range between 30 and 
75%4-9. Furthermore, genome-wide association studies (GWAS) in populations of 
European ancestry have identified common genetic variants associated with CKD 
and kidney function markers10-14 . The largest and most comprehensive genetic 
study is a cross-sectional meta-analysis of GWASs, in which single nucleotide 
polymorphisms (SNPs) at 53 loci were found to be associated with creatinine-
estimated eGFR (eGFRcrea)
15. 
The individual SNPs identified in this meta-analysis can be combined into a 
genetic risk score (GRS)16-18, which summarizes individual genetic predisposition 
to CKD. Such a GRS is a potentially useful tool in etiological and predictive studies 
of CKD. However, because the SNPs were identified in a cross-sectional GWAS 
design, it is uncertain whether a GRS is associated with longitudinal outcomes. 
Furthermore, there is overlap between the 53 loci from the aforementioned meta-
analysis and loci identified in a large GWAS on serum creatinine11,12. Therefore, it is 
difficult to discern whether a GRS corresponds to kidney function per se or partly 
reflects creatinine production/secretion. 
The main study aim was to evaluate the applicability of a GRS, comprising 53 
SNPs identified in cross-sectional GWAS on eGFRcrea, in longitudinal outcomes. 
To this end, we tested three hypotheses. First, we tested the hypothesis that the 
GRS would be associated with kidney outcomes, not only cross-sectionally (i.e. 
with baseline CKD, baseline eGFR), but also longitudinally (i.e. with incident CKD, 
eGFR decline). Second, to assess whether the GRS is a true representation of a 
genetic component to kidney function, we hypothesized that the GRS would also 
be associated with GFR estimates not based on serum creatinine. We therefore 
compared the associations of the GRS with eGFRcrea to those of the GRS with 
an serum cystatin C-estimated GFR (eGFRcysc)
19. Third, to rule out that the GRS 
represents a component to kidney damage rather than kidney function, we 




Study population and design
We used data from the Prevention of REnal and Vascular ENdstage Disease 
(PREVEND) cohort study20. PREVEND was initiated to investigate the natural 
course of increased urinary albumin levels and its association to renal and vascular 
outcomes. Details of this study have been described elsewhere. In brief, 8592 
individuals, sampled from the general population of Groningen, the Netherlands, 
underwent extensive examination between 1997-1998. The four follow-up 
examinations were completed in 2003, 2006, 2008, and 2012. Included were 3649 
subjects of whom GWAS data were available. All subjects gave written informed 
consent. The PREVEND Study was approved by the medical ethics committee of 
the University Medical Center Groningen and conducted in accordance with the 
Helsinki Declaration guidelines.
Genetic risk scores
Genotyping details for PREVEND were described previously21. In brief, genotyping 
was performed on the Illumina CytoSNP12 v2 chip. Variants were imputed to 
1000G22, phase 1 version 3, using Minimac software23. Population stratification 
was assessed by principal component analysis; samples with Z-score>3 for any 
of the first five principal components were excluded, i.e. outlying individuals 
were removed because of likely divergent ancestry24. Samples with a call 
rate<95%, duplicates, and sex discrepancies were excluded. Markers with call 
rate>95%, Hardy-Weinberg equilibrium p-value≥1x10-5, and minor allele 
frequency (MAF)≥1% were included. From the resulting GWAS data, we extracted 
the genotypes of the 53 SNPs that were identified in a recent meta-analysis of 
GWAS on eGFRcrea in European populations
15. Designated risk alleles were those 
associated with lower eGFR. Genotypes were represented as continuous allelic 
dosages from 0 to 2, reflecting an additive model 25. A weighted GRS was defined 
as the sum of the risk alleles weighted for their published regression coefficient. 
Therefore, a higher GRS corresponds to higher susceptibility to impaired kidney 
function. For ease of interpretation, effects are reported per standard deviation 
(sd) higher GRS. 
Outcome measurements and definition
At each examination, participants collected two consecutive 24h-urine specimens 
after thorough instruction. Participants were asked to avoid heavy exercise as 
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much as possible before urine collection, and instructed to postpone urine 
collection in case of urinary tract infection, menstruation, or fever. The collected 
urine was stored cold (4oC) for a maximum of four days before handing it in. After 
this, urine specimens were stored at -20oC. Fasting blood samples were obtained 
and stored at -80oC.
Measurement of serum creatinine was performed by an enzymatic method on 
a Roche Modular analyzer using reagents and calibrators from Roche (Roche 
Diagnostics, Mannheim, Germany), with intra- and interassay coefficients of 
variation of 0.9% and 2.9%, respectively. Serum cystatin C concentration was 
measured by a Gentian cystatin C Immunoassay (Gentian AS Moss, Norway) on a 
Modular analyzer (Roche Diagnostics). Cystatin C was calibrated directly using the 
standard supplied by the manufacturer (traceable to the International Federation 
of Clinical Chemistry Working Group for Standardization of Serum Cystatin C)26 The 
intra- and interassay coefficients of variation were <4.1% and <3.3%, respectively. 
Urinary albumin concentration (UAC) was measured by nephelometry with a lower 
threshold of detection of 2.3mg/L, and intra- and interassay coefficient of variation 
of 2.2% and 2.6%, respectively (Dade Behring Diagnostic, Marburg, Germany). UAC 
was multiplied by urine volume to obtain a value of UAE in mg/24h. The two 
24h-urinary albumin values of each subject per examination were averaged. 
We calculated eGFRcrea from serum creatinine and eGFRcysc from serum cystatin C, 
using the corresponding CKD-EPI equations 19. We defined CKDcrea as eGFRcrea<60ml/
min/1.73m2, CKDcysc as eGFRcysc<60ml/min/1.73m
2, and CKDUAE as UAE≥30mg/24h. 
Incident cases were those free of CKD at baseline who developed CKD during follow-
up. In secondary analyses, we used the CKD-EPI equation for both serum creatinine 
and cystatin C to calculate eGFRcrea-cysc
27. Furthermore, a definition of CKD based on 
KDIGO guidelines (CKDKDIGO, eGFRcrea-cysc<60ml/min/1.73m
2 and/or UAE≥30mg/24h) 
was used28.
Covariates
We selected the following renal risk factors as covariates: age, sex, body-mass index 
(BMI, weight/height2 [kg/m2]), current smoking (self-reported yes/no), diabetes 
(fasting glucose>7.0mmol/L, non-fasting glucose>11.0mmol/L, anti-diabetic 
treatment, or self-reported), hypertension (systolic blood pressure>140mmHg, 
diastolic blood pressure>90mmHg, blood pressure lowering treatment, or self-
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reported), hypercholesterolemia (total cholesterol≥6.21mmol/L, lipid lowering 
treatment, or self-reported), and history of cardiovascular disease (CVD, any 
past cardio/cerebrovascular event or intervention). Covariates were collected at 
baseline by means of questionnaires, anthropometry, and pharmacy records. 
Statistical analyses
Analyses were performed using R3.3.1 and SPSS23.0 (IBM Corporation). Two-sided 
significance level for analyses was set at α=0.05 unless stated otherwise. 
Baseline characteristics
Baseline characteristics were examined for the total population. One-way 
ANOVA, Jonckheere-Terpstra, and χ2-tests were used to examine linear trends of 
characteristics across tertiles of GRS. In subsequent analyses, GRS was treated as 
a continuous variable. We examined age and sex-adjusted associations of all 53 
individual SNPs with baseline eGFRcrea and eGFRcysc using ordinary least squares 
(OLS) regression. 
Cross-sectional associations of the GRS with CKD prevalence and baseline eGFR
Logistic regression was used to examine the association of the continuous GRS 
with baseline CKDcrea. We adjusted for covariates by adding incremental groups 
of covariates in order to distinguish confounding effects of demographics and 
risk factors. Group 1 consisted of age and sex; group 2 additionally included BMI, 
smoking, diabetes, hypertension, hypercholesterolemia, and history of CVD. 
We examined the association of the GRS with continuous eGFRcrea using OLS 
regression. We adjusted for covariates as described above. Analyses were 
repeated for baseline eGFRcysc and prevalent CKDcysc. 
Longitudinal associations of the GRS with CKD incidence and eGFR decline
Cox regression models were used to examine the association of continuous GRS 
with incident CKDcrea. To estimate time to incident CKDcrea, we used a midpoint 
imputation technique. In this analysis, we corrected for baseline eGFRcrea in 
addition to the previously listed renal risk factors. Subjects were censored at 
death or date of last visit.
Linear mixed-effects (LME) analysis was performed to examine the association 
of the GRS with eGFR decline. We modelled eGFRcrea as a function of time since 
105 Evaluation of a GRS based on eGFRcrea
5
baseline (per year). We specified a model with random intercept, random coefficient 
for time, and unstructured covariance matrix. The GRS, time, and covariates were 
included as fixed effects. A two-way interaction term between GRS and time was 
introduced to assess whether eGFRcrea decline differed by values of the GRS. 
Analyses were repeated with the outcomes eGFRcysc decline and incident CKDcysc. 
Associations with UAE
We repeated the cross-sectional and longitudinal analyses described above 
to examine associations of a GRS with renal outcomes based on elevated UAE. 
Continuous UAE was transformed by its natural logarithm to approach normality 
(ln(UAE)), in OLS regression and LME analyses. 
Secondary analyses
We repeated all analyses using eGFRcrea-cysc and CKDKDIGO as outcome. Furthermore, 
we constructed two alternative GRS. The first alternative GRS comprised 49 
SNPs that were significant in the meta-analysis by Gorski et al.14, with the second 
alternative comprising all 63 SNPs identified in either the Pattaro (53 SNPs) and 
the Gorski study (10 additional SNPs). 
RESULTS
Baseline characteristics
Baseline characteristics of the 3649 subjects are presented in Table 1. In univariable 
analyses, a higher tertile for the GRS was associated with higher serum creatinine 
and cystatin C levels (ptrend<0.001); higher prevalence of CKDcrea (ptrend =0.002) and 
CKDcysc (ptrend =0.01); lower eGFRcrea (ptrend end<0.001) and lower eGFRcysc (ptrend 
<0.001); lower UAE (ptrend <0.001). No associations with CKDUAE were found. We 
found no associations with age, sex, BMI, smoking status, diabetes, hypertension, 
hypercholesterolemia, or history of CVD.
Details of the 53 SNPs used in the calculation of the GRS and age- and 
sex- adjusted estimates of their association to baseline eGFRcrea, baseline 
eGFRcysc, and ln(UAE) are listed in Supplementary Table S1A. Out of 53 
SNPs, 22 reached nominal significance (one-sided p<0.05), while three were 
significant when a Bonferroni correction for 53 tests (p<9.4x10-4) was applied. 
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N 3649 1216 1217 1216 n/a
Age, years 49 [39-60] 49 [40-60] 49 [39-59] 49 [39-60] 0.954
Males, % 52% 51% 51% 52% 0.598
BMI, kg/m2 26 (4.3) 26 (4.2) 26 (4.4) 26 (4.2) 0.816
BMI ≥30, % 16% 16% 16% 16% 0.868
Current smoker, % 35% 35% 35% 36% 0.420
Hypertension, % 34% 32% 36% 34% 0.521
SBP, mmHg 129 (20) 129 (20) 129 (20) 129 (20) 0.612
DBP, mmHg 74 (9.9) 74 (9.9) 74 (10) 74 (9.9) 0.887
BP lowering medication, % 12% 13% 14% 11% 0.658
Diabetes, % 3.9% 3.7% 3.4% 4.7% 0.210
Glucose, mmol/L 4.7 [4.3-5.1] 4.7 [4.4-5.1] 4.7 [4.3-5.2] 4.7 [4.4-5.1] 0.926
Anti-diabetic medication, % 1.3% 1.2% 1.0% 1.8% 0.843
Hypercholesterolemia, % 31% 31% 32% 31% 1.000
Total cholesterol, mmol/L 5.7 (1.1) 5.7 (1.1) 5.6 (1.1) 5.7 (1.1) 0.744
Lipid lowering medication, % 3.6% 4.8% 3.7% 2.7% 0.499
History of CVD, % 4.2% 3.9% 5.1% 3.8% 0.920
Serum creatinine, mg/dL 0.82 (0.18) 0.79 (0.16) 0.82 (0.18) 0.85 (0.19) <0.001
eGFRcrea , mL/min/1.73m
2 96 (16) 98 (15) 96 (16) 94 (16) <0.001
CKDcrea: eGFRcrea <60, % 2.5% 1.4% 2.7% 3.4% 0.002
Serum cystatin C, mg/L 0.90 (0.18) 0.88 (0.17) 0.90 (0.19) 0.92 (0.18) <0.001
eGFRcysc , mL/min/1.73m
2 92 (19) 94 (19) 92 (19) 90 (19) <0.001
CKDcysc: eGFRcysc <60, % 5.9% 4.9% 5.3% 7.4% 0.010
eGFRcrea-cysc 94 (17) 97 (17) 95 (17) 92 (17) <0.001
CKDKDIGO :eGFRcrea-cysc<60 or UAE≥30 , % 20% 21% 20% 19% 0.297
UAE, mg/24h 10.6 [6.6-21] 11.5 [7.0-23] 10.3 [6.6-20] 10.2 [6.4-20] <0.001
UAE ≥30 , % 17% 19% 17% 17% 0.172
No of risk alleles 57 (4.5) 52 (2.7) 57 (1.7) 62 (2.5) <0.001
Baseline characteristics of the cohort. Data is presented as mean (standard deviation), median [interquartile range], and percentage 
where appropriate. P-values for linear trend were calculated using one-way ANOVA, Jonckheere-Terpstra-tests, and χα2-tests where 
appropriate. 
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate; GRS, genetic risk score; SBP, systolic blood pressure; UAE, urinary albumin excretion
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Supplementary Figure S2 presents a plot of age- and sex-adjusted regression 
coefficients. These coefficients were obtained by OLS regression of individual 
SNPs on either eGFRcrea and eGFRcysc. Correlation between the regression 
coefficients on eGFRcrea and eGFRcysc was moderate (Pearson r=0.51, p<0.001). The 
total least squares regression line showed fair agreement with the line of identity. 
Cross-sectional associations of the GRS with baseline eGFR and CKD 
prevalence
We present cross-sectional results in Table 2. Per sd higher GRS, the odds of having 
CKDcrea at baseline increased by 41% (fully adjusted odds ratio (OR) (95%CI)=1.41 
(1.12;1.77), p=0.002. A higher GRS was associated with lower eGFRcrea (fully adjusted 
unstandardized coefficient B (95%CI)= -2.05 (-2.45;-1.65) mL/min/1.73m2, p<0.001), 
independent of known risk factors. Effect sizes of the associations with CKDcysc 
(adjusted OR (95%CI)= 1.27 (1.08;1.50), p=0.004) and with eGFRcysc (adjusted B 
(95%CI)= -1.63 (-2.11;-1.14) mL/min/1.73m2, p<0.001) were smaller but showed a 
similar trend compared to those for creatinine-estimated outcomes. Estimates of 
the effect sizes of the GRS on both eGFRcrea and eGFRcysc remained stable during 
incremental covariate adjustment. 
Longitudinal associations of the GRS with eGFR decline and CKD incidence
We present longitudinal results in Table 3. A higher GRS was associated with 
higher incidence of CKDcrea after adjustment for known renal risk factors (adjusted 
hazard ratio (HR) (95%CI)=1.28 (1.09;1.50), p=0.003), but significance disappeared 
after additional adjustment for baseline eGFRcrea (fully adjusted HR (95%CI)=1.05 
(0.89;1.24), p=0.537). A higher GRS was not associated with steeper decline of 
eGFRcrea (fully adjusted B (95%CI)= -0.01 (-0.04;0.03) mL/min/1.73m
2 per year, 
p=0.655). Inclusion of interaction terms between baseline renal risk factors and 
time did not change estimates of the effects between the GRS and eGFR decline 
(data not shown).
Similar associations were found with eGFRcysc decline (fully adjusted B (95%CI)= 
-0.03 (-0.07;0.01) mL/min/1.73m2 per year, p=0.167) and incident CKDcysc (adjusted 
HR (95%CI)=1.17 (1.03;1.32), p=0.014. The association with incident CKDcysc lost 
significance after additional adjustment for baseline eGFRcysc (fully adjusted HR 
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Association of the GRS with UAE
Results of analyses on UAE are presented in Table 2-3. A higher GRS was associated 
with lower ln(UAE) (fully adjusted B (95%CI)= -0.04 (-0.07;-0.01) ln(mg/24h), p=0.004) 
but not with higher prevalence of CKDUAE (fully adjusted OR (95%CI)=0.92 (0.84;1.01), 
p=0.074). No longitudinal associations of GRS with kidney damage were observed: a 
higher GRS was neither associated with steeper increase of ln(UAE) (fully adjusted B 
(95%CI)=0.001 (-0.001;0.004) ln(mg/24h) per year, p=0.297) nor with higher incidence 
of CKDUAE (fully adjusted HR (95%CI)=1.03 (0.93;1.14), p=0.360). 
Analyses with 24h-urinary albumin-to-creatinine ratio as outcome yielded similar 
results (data not shown).
Secondary analyses
Associations of the GRS with eGFRcrea-cysc were consistent with those of the GRS 
with eGFRcrea and eGFRcysc. We found no cross-sectional or longitudinal association 
of the GRS with CKDKDIGO (Table 2-3). Two alternative GRS, based on 49 SNPs 
(GRS1000G-49) and 63 SNPs (GRS1000G-63), were evaluated. Individual SNP-effects of 
these GRS are listed in Supplementary Table S1B. The GRSs showed similar but 
slightly weaker associations compared to our main GRS (Supplementary Table S3-7). 
DISCUSSION
In this population based, longitudinal cohort study, we evaluated the effects of 
a GRS comprising 53 eGFRcrea-SNPs on kidney outcomes. To this end, we tested 
cross-sectional and longitudinal associations of this GRS with CKDcrea and eGFRcrea 
and compared these associations to those with CKDcysc and eGFRcysc. Cross-
sectional associations of the GRS with the kidney outcomes, CKDcrea and eGFRcrea, 
were modest but robust, corroborating the literature. In longitudinal analyses, we 
observed no associations with kidney function decline. The GRS was associated 
with incidence of CKDcrea, but this was likely due to lower baseline eGFR rather than 
accelerated kidney function decline. In comparison to associations with eGFRcrea, 
associations with eGFRcysc were smaller but showed a similar trend. Higher GRS 
was not associated with kidney damage markers. Furthermore, all associations 
of the GRS with kidney outcomes were independent of renal risk factors. These 
data suggest that the GRS is a true representation of the genetics underlying 
kidney function, as opposed to creatinine metabolism, kidney damage, or related 
etiologies such as hypertension/diabetes. 
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In secondary analyses, we confirmed associations with eGFRcrea-cysc, currently 
the best estimate for kidney function for large population-based studies 19,29. We 
found no association of the GRS with CKDKDIGO as outcome. This is likely due to the 
fact that this GRS was optimized for eGFR as outcome and not urinary albumin; 
in our sample, CKDKDIGO was predominantly characterized by elevated urinary 
albumin rather than diminished kidney function. Two alternative GRS (GRS1000G-49 
and GRS1000G-63), yielded similar results but proved to be slightly less powerful 
predictors of kidney function and CKD in this sample.
Previously, two similar GRSs based on eGFRcrea SNPs were investigated in ~2500 
participants with ~11 years of follow-up from the Framingham Heart Study. 
O’Seaghdha et al. calculated a 16-SNP GRS for eGFRcrea
17. This sample of the 
Framingham cohort was revisited by Ma et al.18, who updated the GRS with 37 
additional SNPs, that is the same 53 as the present study. Both of these GRS 
were independently associated with incident CKD (eGFRcrea<60mL/min/1.73m
2), 
although neither of these GRSs improved prediction and/or discrimination beyond 
clinical risk factors (age, sex, BMI, eGFR, hypertension, diabetes, proteinuria). 
Interestingly, they reported associations of a higher GRS with a higher incidence 
of CKD to be independent of baseline eGFR, hence an accelerated deterioration 
of kidney function in those with a higher GRS. Such an effect was also suggested 
by Böger et al.30 in a study of eGFR related loci identified by GWAS. In 26,308 
individuals of European ancestry, the associations of 16 separate SNPs known 
at the time with incident CKD were examined. Of these 16 SNPs, six (mapping 
to UMOD, PRKAG2, LASS2, DAB2, DACH1, and STC1) were significantly (p<0.05) 
associated with incident CKD (eGFR<60mL/min/1.73m2), even after correction for 
baseline eGFR. Similar to the findings of O’Seaghdha and Ma et al, this implies 
that several SNPs associate with eGFR decline. In contrast, in the present study 
we could not corroborate such an effect on CKD incidence or eGFR decline: the 
association of GRS with incident CKD was not significant after adjustment for 
baseline eGFR, and there was no significant association between the GRS and 
eGFR decline. 
A possible explanation for this discrepancy is the potential overestimation of 
the effect of the GRS by O’Seaghdha and Ma et al. due to the participation of 
the Framingham Cohort Study in the discovery phase of the meta-analysis12,15. 
Similarly, overestimation of individual SNP effects may have occurred in the 
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study by Böger et al, given that seven of the eight cohorts participating in that 
study were part of the discovery GWAS12. Such overlap in discovery and validation 
cohorts might result in inflated effect sizes31. The PREVEND study was not part 
of the original discovery GWAS, ensuring its independence and suitability as a 
validation cohort for evaluation of a GRS based on eGFRcrea SNPs. This potential 
overestimation possibly also explains that in our study, the GRS explained only 
1.66% of variance of baseline eGFRcrea, whereas in the original GWAS, the explained 
variance of eGFRcrea by the combined loci was 3.22%
15. 
Notwithstanding these discrepancies, the combined data suggest that the genetics 
underlying kidney function are, at least partly, distinct from that underlying kidney 
function decline and/or kidney disease susceptibility. Our results indicate that a 
GRS based on cross-sectional GWAS results on kidney function is not clinically 
applicable (e.g. in the prediction of CKD risk). A GRS would be more applicable 
if SNPs associated with kidney function decline and/or CKD incidence were 
used, as these would likely better represent disease susceptibility. Unfortunately, 
there is paucity of data on genetic loci associated with kidney function decline 
or CKD incidence. To the best of our knowledge, only one study by Gorski et 
al. performed a GWAS for kidney function decline phenotypes32. In this study, 
only one SNP mapping to UMOD (which was also implicated in prior GWAS on 
cross-sectional eGFRcrea) was significantly associated with eGFR change in the 
general population, while two novel loci, CDH23 and GALNT15/GALNT11 were only 
suggestively associated with eGFR change in CKD patients, and rapid decline in 
the general population, respectively. To benefit clinical applicability, we argue 
that future GWAS should focus on disease susceptibility genes, i.e. loci associated 
with eGFR decline and/or CKD incidence. We found a higher GRS to be associated 
with lower UAE, i.e. lower risk of kidney damage, which is surprising for two 
reasons. First, a prior family study, using bivariate variance component linkage 
analysis techniques, found a low genetic correlation between eGFR and UACR 
(rg=0.002 in African Americans, not reported for European Americans)
5. Second, 
there is no overlap in genome-wide significant markers for eGFR and albuminuria 
in the general population33, 34. Due to this apparent lack of genetic overlap, it is 
believed that eGFR and albuminuria have distinct genetic underpinnings. To our 
knowledge, we are the first to observe this counterintuitive association with the 
updated 53 SNP GRS. Although the correlation between the GRS and ln(UAE) was 
weak (r=-0.043), it is unlikely to be a chance finding: in an earlier study by Ellis et al. 
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a weighted GRS (comprising 16 SNPs associated with eGFRcrea) was associated 
with both lower eGFR and with lower UACR35. The authors attributed this effect 
to the A-allele of rs17319721, a SNP mapping to SHROOM3, because exclusion 
of this SNP from their GRS attenuated the effect on UACR. In previous GWAS, 
the SHROOM3 SNP was found to be associated with eGFRcrea
12, and suggestively 
with UACR (p=7.0x10-7)15,33,34. In the present study, exclusion of this SNP from the 
updated GRS did not attenuate the effect (data not shown). Therefore, it is possible 
that, in addition to SHROOM3, other loci discovered in the recent meta-analysis 
on eGFRcrea might have pleiotropic effects on both eGFR and albuminuria. We 
therefore performed a query in LDHub v1.3.1, a platform for LD-score regression 
which uses original GWAS summary statistics36, 37. LD Hub showed a modest genetic 
correlation between eGFRcrea and UACR (rg=0.388, p<0.001), and a suggestive 
genetic correlation between eGFRcysc and UACR (rg=0.195, p=0.087), in the same 
direction as our findings (i.e. higher eGFR~higher UACR). These correlations 
suggest that there is at least partial overlap in the genetics underlying eGFR and 
albuminuria. Addressing the question of pleiotropy is beyond the scope of the 
present study and requires dedicated analysis in larger samples.
A number of SNPs identified in the GWAS on eGFRcrea may be linked to loci related 
to creatinine production or secretion, hence not with kidney function per se38. We 
therefore examined two SNPs mapping to loci known to be related to creatinine 
metabolism: rs2467853 which maps to the creatinine production locus GATM39 and 
rs316009 which maps to the creatinine secretion locus SLC22A240. For both SNPs, 
we observed an inconsistency in the direction of effect for baseline eGFRcrea and 
eGFRcysc (see Supplementary Table 1A), suggesting that these loci are indeed not 
related to kidney function. Exclusion of these SNPs led to a slightly improved GRS: 
effects of this GRS on eGFRcrea and eGFRcysc more closely resembled each other 
than those of the main GRS, although this improvement was only slight (data not 
shown). Our conclusions therefore remain unchanged. Future, functional studies 
may investigate other presumptive creatinine-related loci. The exclusion of such 
loci may result in a GRS that more accurately reflects genetic predisposition to 
kidney function.
To our knowledge, we are the first study that examined the association between 
a GRS comprising 53 SNPs and eGFR decline. Strengths of this study include the 
availability of serially measured creatinine and cystatin C, as well as two 24h-urinary 
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albumin at each examination, during a considerable follow-up duration of 11 years. 
A major strength of PREVEND is its independence from the discovery GWAS that 
identified the 53 SNPs used in the GRS, resulting in unbiased effect estimates of 
the GRS. Given that participants of the PREVEND GWAS sample are of European 
ancestry, we cannot generalize to other ethnicities. Finally, we could not calculate 
genetic correlations between eGFR levels and eGFR decline as GWAS summary 
results for eGFR decline were currently not available.
In conclusion, a GRS comprising 53 SNPs showed modest but robust associations 
with cross-sectional CKD outcomes based on eGFRcrea. These associations were 
confirmed with eGFRcysc, which highlights the potential usefulness of a GRS 
as a representation of the genetics underlying kidney function. However, no 
longitudinal associations with incident CKD or eGFR decline were found. Given 
these results, we question the clinical utility of cross-sectional GWAS results 
on kidney function. We suggest that future GWAS specifically examine genetic 
associations with eGFR decline and/or CKD incidence. These GWAS may identify 
loci that, when incorporated into a GRS, will improve the clinical utility of this 
score, e.g. in predicting onset of CKD. 
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